**A Review of Herbal Therapy in Multiple Sclerosis**

Sina Mojaverrostami¹,², Maryam Nazm Bojnordi¹,², Maryam Ghasemi-Kasman¹,², Mohammad Ali Ebrahimzadeh³,⁴, Hatif Ghasemi Hamidabadi¹,²,⁵

¹ Young Researchers and Elite Club, Behshahr Branch, Islamic Azad University, Behshahr, Iran.
² Department of Anatomy & Cell Biology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
³ Cellular and Molecular Research Center, Department of Anatomy & Cell Biology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
⁴ Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
⁵ Pharmaceutical Sciences Research Center, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

**Abstract**

Multiple sclerosis is a complex autoimmune disorder which characterized by demyelination and axonal loss in the central nervous system (CNS). Several evidences indicate that some new drugs and stem cell therapy have opened a new horizon for multiple sclerosis treatment, but current therapies are partially effective or not safe in the long term. Recently, herbal therapies represent a promising therapeutic approach for multiple sclerosis disease. Here, we consider the potential benefits of some herbal compounds on different aspects of multiple sclerosis disease. The medicinal plants and their derivatives; Ginkgo biloba, Zingiber officinale, Curcuma longa, Hypericum perforatum, Valeriana officinalis, Vaccinium macrocarpon, Nigella sativa, Piper methysticum, Crocus sativus, Panax ginseng, Boswellia papyrifera, Vitis vinifera, Gastrodia elata, Camellia sinensis, Oenothera biennis, MS14 and Cannabis sativa have been informed to have several therapeutic effects in MS patients.

**Introduction**

Multiple sclerosis (MS) is an autoimmune disease that mostly occurs in young adulthood.¹ The etiology of MS disease is still not well understood, but both genetic and environmental factors were found to have important roles in MS disease initiation or progression.² In MS disease, inflammatory cells demolish myelin sheath in the CNS which weakens action potential conduction.³ Two cardinal properties of MS are acute inflammation that associated with demyelination and another one is axonal loss.⁴ After injury, oligodendrocyte precursor cells (OPCs) which are residing at parenchyma continuously produce myelinating oligodendrocytes.³⁻⁵ In addition, regarding to the ability of neural stem cells for differentiation to OPCs, these stem cells are considered as an important source for remyelination.⁶⁻⁸ These endogenous stem cells proliferate, migrate and differentiate to OPCs after brain injuries. However, endogenous OPCs can produce myelin and improve some aspects of the MS disease, but endogenous repair may fail in long term.⁹⁻¹⁰ Therefore, several studies have focused on different approaches (including targeting specific signaling pathways, stem cell therapy, suppressing the inflammation process and reprogramming of glial cells to OPCs …) that improve myelination.¹⁰ Despite the potential benefits of stem cell therapy in the improvement of myelin repair,¹¹ its clinical application has been hampered because of the possibility of teratoma formation, cell rejection and ethical problems.¹²⁻¹³ Therefore, there is still a need for developing new drugs which have no or less considerable side effects. The pathophysiology of MS is not well elucidated, which makes its’ treatment strategy very difficult and perplexing.¹⁴ At the present time, most of the strategies in MS treatment are focused on preventing of inflammation in the CNS.¹⁵ Interferon beta (IFN-beta) was firstly confirmed as an effective drug for treatment of MS in 1993.¹⁶ Afterward, different drugs were introduced for curing MS such as glatiramer acetate, natalizumab, alemtuzumab and fingolimod.¹⁴ All of these mentioned drugs were partially effective and their remarkable adverse effects makes them unsuitable for prolonged use.¹⁷ For example, several studies indicated the adverse effects of IFN-beta consumption including, stroke, headache, migraine and depression.¹⁷ Until now, no absolute treatment has been found for MS, therefore,

*Corresponding author: Sina Mojaverrostami, Tel: +98 21 64432348, Fax: 98 21 66419072, Email: sinamojaer@gmail.com

© 2018 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution [CC BY], which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
trying to find a completely effective and safe treatment is still ongoing. Use of complementary and alternative medicine (CAM), in particular herbal remedies have noticeably risen in MS patients over the last decades.\textsuperscript{18,19} Herbal therapy is known as a helpful strategy for curing the different disorders from ancient to the present time.\textsuperscript{20} Previous studies reported that medicinal plants have several therapeutic effects in different disorders such as cancers, diabetes and neurodegenerative diseases.\textsuperscript{21,22} Recently, a growing number of findings have indicated that some herbal compounds improve myelin repair and lead to suppression of inflammation.\textsuperscript{23,24} Also, there are many studies that reported the anti-inflammatory and antioxidant effects of medicinal plants, as well as other helpful properties which make them as a natural, safe and reliable remedy for treatment of neurodegenerative diseases.\textsuperscript{25,26} Pervious studies have indicated that MS patients are interested in using herbal medicines to control their disease symptoms.\textsuperscript{26} For example in China, Chinese herbal medicine (CHM) is widely used by MS patients for ameliorating the severity of disease.\textsuperscript{27} The beneficial effects of CHM in MS disease is occured by reduction of the severity of MS disease; including antioxidative properties, anti-apoptotic effects, anti-inflammatory properties and promoting the differentiation of local stem cells to myelin producing cells.\textsuperscript{28} MS patients usually use CAM, and medicinal plants as a member of this family plays a crucial role to cure MS and its\textsuperscript{2} associated symptoms.\textsuperscript{29} Different herbal medicines are recommended for MS patients, but the understanding of their efficacy is not well described. In this review; we will discuss some of herbal compounds beneficial effects on MS disease (Table 1 and Table 2). We conducted a search for all English language articles in Google Scholar, Science Direct, Scopus, PubMed and Medline for medicinal plants, that have been used for their therapeutic potentials in MS disease, studies which their publication dates from January 1960 to April 2018 were used.

### Table1. Summary of herbal medicines used in the treatment of Multiple sclerosis

| Plant               | Author (Country) | Design of study | Dosage                  | Number  | Duration of study | Effects                                                                 | Ref   |
|---------------------|------------------|-----------------|-------------------------|---------|------------------|--------------------------------------------------------------------------|-------|
| Ginkgo biloba       | Johnson et al (USA) | Clinical trial-Double-blind, placebo-controlled | 240 mg/day of ginkgo extract | 22 MS patients | 4 weeks | Treatment with ginkgo extract relieved fatigue with no adverse effect in MS patients | 34    |
|                     | Lovera et al (USA) | Clinical trial-Double-blind, placebo-controlled | 240 mg/day of ginkgo extract | 38 MS patients | 12 weeks | Improvement of the cognitive performance were reported in treated group | 37    |
|                     | Brochet et al (France) | Clinical trial-Double-blind, placebo-controlled | 240 mg/day of ginkgo extract | 104 MS patients | 1 week | ginkgolide B was not an effective treatment for exacerbations of MS | 180   |
| Curcuma longa       | Jaafarzadeh et al (Iran) | EAE model of MS in mice | 200 and 300 mg/kg ginger extract | 24      | 4 weeks | Ginger extract ameliorated EAE severity and modulated the expression of IL-27, IL-33 | 43    |
|                     | Xie et al (Japan)  | EAE model of MS in rats | 100 and 200 mg/kg curcumin extract | 21      | 2 weeks | Curcumin decreased the inflammation and the severity of EAE | 53    |
|                     | Natarajan and Bright (USA) | EAE model of MS in SJL/J mice | 50 and 100 µg curcumin in 25 µl DMSO / day | -       | 4 weeks | Curcumin decreased CNS inflammation and demyelination also, decreased the severity of EAE | 54    |
|                     | Mohajeri et al (Iran) | EAE model of MS in rats | 12.5 mg/kg of curcumin | 20      | 17 days | Treatment with polymerized nano-curcumin decreased the severity of EAE and increased the remyelination | 23    |
| Oenothera biennis   | Firoozi et al (Iran) | Double blind, randomized clinical trial | 18–23 g/day Evening primrose oil and C. sativa oils | 100 MS patients | 24 weeks | Treatment with co-supplemented C. sativa and evening primrose oils decreased the clinical score in MS patients | 158   |
|                     | Horrobin (Canada)  | Double blind, randomized clinical trial | - | 14 MS patients | 24 weeks | Treatment with colchicine and evening primrose oil improved manual dexterity test and clinical score in MS patients | 159   |
| Hypericum perforatum| Naziroglu et al (Turkey) | In-vitro study on neutrophils of MS patients | 20 µM/ml H. perforatum for 2 hours | 9 MS patients | - | Treatment with H. perforatum indicated the protective effects on oxidative stress in MS patients | 69    |
| Vaccinium macrocarpon| Gallien et al (France) | Double blind, clinical trial, placebo-controlled | 36 mg/day Cranberry extract(proanthocyanidins) | 171 MS patients | 1 year | Treatment with cranberry extract versus placebo did not prevent UTI occurrence in MS patients | 81    |
| Nigella sativa      | Fahmy et al (Egypt) | EAE model of MS in rats | 2.8 g/kg Nigella sativa extract | 22      | 4 weeks | N. sativa ameliorated the clinical signs of EAE, suppressed inflammation and enhanced remyelination in the CNS | 85    |
|                     | Noor et al (Egypt) | EAE model of MS in rats | 2.8 g/kg Nigella sativa extract | 22      | 4 weeks | N. sativa suppressed inflammation in EAE rats. Also, N sativa enhanced remyelination in the cerebellum and reduced the expression of TGF β1 | 87    |
### Herbal Therapy for Multiple Sclerosis

| Plant | Author (Country) | Design of study | Dosage | Number | Duration of study | Effects | Ref |
|-------|------------------|-----------------|--------|--------|------------------|---------|-----|
| *Cannabis sativa* | Ghaffari et al (Iran) | EAE model of MS in rats | Intra-hippocampal (Sand 10 μg/rat) injection of the saffron | 35 | 3 days | Local injection of saffron extract modulated the oxidative stress markers (reduced the activity of GPx and SOD enzymes), through scavenging of ROS | 103 |
| | Ghazavi et al (Iran) | EAE model of MS in C57Bl/6 mice | 100 μL saffron extract | 20 | 3 weeks | Treatment with saffron decreased inflammation in the spinal cord and decreased the severity of EAE | 102 |
| *Camellia sinensis* | Hwang et al (Korea) | EAE model of MS in C57Bl/6 mice | 200 μg of an acidic polysaccharide of Panax ginseng | - | 33 days | Acidic polysaccharide of Panax ginseng decreased the infiltration of inflammatory cells in the CNS, also suppressed EAE score by inhibiting the proliferation of T cells and the production of inflammatory cytokines | 113 |
| | Etemadifar et al (Iran) | Randomized Double-blind, placebo-controlled | 250 mg ginseng tablets | 52 MS patients | 12 weeks | Ginseng treatment had no adverse effect on MS patients as well as reduced fatigue and had a positive effect on quality of life | 114 |
| *Vitis vinifera* | Sedighi et al (USA) | Randomized, double-blinded, placebo-controlled study | 600 mg of B. papyrifera | 80 MS patients | 8 weeks | B. papyrifera improved the visuospatial memory of MS patients | 124 |
| | Sato et al (USA) | EAE model of MS in C57Bl/6 mice | 20 mg/kg per day | - | 8 weeks | Resveratrol treatment worsened the demyelination and inflammation without neuroprotective effects in the CNS | 129 |
| | Kelly et al (USA) | EAE model of MS in C57Bl/6 mice | 100 and 250 mg/kg Sigma resveratrol | - | 4 weeks | Resveratrol delayed the onset of EAE and had a significant neuroprotective effect as well as prevents neuronal loss | 130 |
| | Shindler et al (USA) | EAE model of MS in SJL/J mice | 500 and 1000 mg/kg resveratrol | 62 | 4 weeks | Resveratrol treatment prevented neuronal loss during optic neuritis and reduced neurological dysfunction during EAE | 131 |
| *Panax ginseng* | Mahler et al (Germany) | Randomized, double-blinded, placebo-controlled study | 600 mg/d EGCG | 18 MS patients | 12 weeks | Treatment with EGCG improved muscle metabolism during moderate exercise in MS patients | 155 |
| | Tafreshi et al (Iran) | EAE model of MS in C57Bl/6 mice | MS14 containing 30% of the diet | 14 | 20 days | Treatment with MS14 ameliorated the clinical signs of EAE and reduced neuropathological changes | 163 |
| | Kalan et al (Iran) | EAE model of MS in C57Bl/6 mice | MS14 containing 30% of the diet | 25 | 35 days | MS14 decreased EAE symptoms and lymphocyte infiltration into the CNS | 164 |
| | Kalan et al (Iran) | EAE model of MS in C57Bl/6 mice | MS14 containing 30% of the diet | 25 | 35 days | Treatment with MS14 reduced clinical signs of EAE, demyelination and IL-6 production | 165 |
| *Cannabis sativa* | Zajicek et al (UK) | Randomized, placebo-controlled trial | Capsules containing 2.5 mg of THC and 1.25 mg of cannabidiol | 630 MS patients | 15 weeks | Cannabinoids improved patients' mobility and improved in spasticity | 173 |
| | Zajicek et al (UK) | Double blind, placebo controlled, phase III study | Capsules containing cannabidiol 0.8–1.8 mg and 2.5 mg THC | 279 MS patients | 12 weeks | Treatment with cannabinoids improved the relief from muscle stiffness in MS patients | 172 |
| | Wade et al (UK) | Double blind, randomized, placebo-controlled study | 120 mg cannabidiol and 120 mg THC | 160 MS patients | 10 weeks | Treatment with cannabinoids improved patient's spasticity, without any adverse effects | 174 |
| | Greenberg et al (USA) | Double blind, randomized, placebo-controlled study | Smoking one marijuana cigarette containing 1.54% THC | 10 MS patients | 3 days | Smoking marijuana improved eyes-open and eyes-closed tests, and noise variance values | 178 |
| | Brady et al (USA) | Open-label, pilot study | 2.5 mg of THC and 2.5 mg CBD per spray | 10 MS patients | 8 weeks | Cannabinoids decreased urinary urgency, number and volume of incontinence episodes, frequency and nocturia in MS patients. Also, spasticity and quality of sleep improved significantly in the treated group | 179 |
**Table 2. Use of herbal medicines in Multiple sclerosis, according to the symptomatic problems**

| Usage                          | Plant                                      | References |
|-------------------------------|--------------------------------------------|------------|
| Antidepressant                | Hypericum perforatum                        | 69,101     |
|                               | Crocus sativus                             | 73,93      |
| Sleeping problem              | Piper methysticum                          | 36,124     |
|                               | Valeriana officinalis                       |            |
| Improvement in cognitive impairment | Ginkgo biloba                                | 79,179     |
|                               | Boswellia papyrifera                        |            |
| Urinary system dysfunction     | Vaccinium macrocarpon                      |            |
|                               | Cannabis sativa                            |            |
| Fatigue                       | Ginkgo biloba                              | 114,34     |
|                               | Panax ginseng                              |            |
|                               | Ginkgo biloba                              |            |
|                               | Zingiber officinale Curcuma longa           |            |
|                               | Oenothera biennis                          |            |
|                               | Nigella sativa                             |            |
|                               | Crocus sativus                             |            |
|                               | Panax ginseng                              | 33,34,87,101,113,124,130,14                 |
|                               | Boswellia papyrifera                        | 0,134,159,164,167                           |
|                               | Vitis vinifera                             |            |
|                               | Gastrodia elata                            |            |
|                               | Camellia sinensis                          |            |
|                               | Cannabis sativa                            |            |
|                               | MS14                                       |            |

**Ginkgo biloba**  
*Ginkgo biloba* L. (well-known as ginkgo), is one of the oldest living tree species from the family *Ginkgoaceae*. Ginkgo is native to Korea and China, but now it can be found all over the world. Ginkgo refers to an extract of the leaves of the *G. biloba* trees, which traditionally used as a remedy to improve the mental alertness and memory. The current reputation of *G. biloba* can be attributed to a pioneering research that informed *G. biloba* is an effective cure for cognitive issues. Studies have shown that anti-inflammatory and inhibiting the platelet-activating factor (PAF) properties of ginkgo extract (EGB761) are effective on MS disease. Ginkgolides is the major component of *G. biloba*, its effect on the PAF activity represents the possible therapeutic role of this plant on MS. PAF’s role in inflammation process is obviously introduced, so ginkgo can inhibit this process. In addition, ginkgo reverses cognitive impairment and reduces fatigue in MS patients. *G. biloba* is generally safe with no side or adverse effects but in some few cases, dizziness, headaches and ocular bleeding associated with its usage. Consumption of *G. biloba* is almost safe and has obvious therapeutic effects for MS patients; improving functional status (fatigue) of people with MS and neuroprotective activities are the valuable medical properties of *G. biloba*.

**Zingiber officinale**  
*Zingiber officinale* Roscoe (Ginger), is an aromatic plant in the family Zingiberaceae. *Z. officinale* is native to India and commonly grown in Asia, tropical Africa and Latin America. Ginger root is routinely used as an aromatic spice and a traditional drug. Recent studies acknowledged the anti-cancer, antioxidant and anti-inflammatory activities of ginger. Anti-inflammatory capacity of ginger is the reason of its consumption by MS patients. Gingerols and its dehydrated derivatives (shogaols), are the major components of the ginger that exhibit anti-inflammatory effects. The anti-inflammatory effects of 6-shogaol were reported by inhibiting the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in macrophages, as well as preventing dopamine reduction and reducing apoptosis rate in CNS. 10-gingerol is another important component of ginger which attributed with anti-inflammatory effect in fresh ginger. 10-gingerols inhibits LPS-induced NO and production of pro-inflammatory cytokines by inhibiting the NF-jB activation. Positive effects of ginger and its’ active compounds (6-shogaol and 10-gingerol) were approved in animal models of MS, by exerting anti-inflammatory and neuroprotective effects, but still clinical studies on MS patients are needed to confirm these results.

**Curcuma longa**  
*Curcuma longa* L. is a tropical plant, native to southern and southeastern tropical Asia. *C. longa* is belonging to the ginger family, *Zingiberaceae*. A yellow coloring-matter obtained from the roots of *C. longa*, is named curcumin. Curcumin is widely used as a dietary spice and pigment. Curcumin is commonly consumed as an Asian folk remedy for treating biliary disorders, anorexia, cough, sinusitis and sore throat. Studies indicated that curcumin exerts a wide range of biological activities, including anti-inflammatory, antitumor and antioxidants effects.

---

578 | *Advanced Pharmaceutical Bulletin*, 2018, 8(4), 575-590
Anti-inflammatory effect of curcumin has been obviously examined in different studies. Curcumin does its anti-inflammatory role in two major ways: (1) inhibition of pro-inflammatory cytokines and (2) inhibition of Th17 differentiation and its related pathways. Curcumin ameliorated the severity of experimental autoimmune encephalomyelitis (EAE), as a animal model of MS disease, also reduced the infiltration of inflammatory cells to the CNS. Curcumin modulates inflammatory process by decreasing the expression of the different pro-inflammatory and inflammatory cytokines. In one study, polymerized form of nanocurcumin was used for treating EAE model of MS, which demonstrated anti-inflammatory and antioxidative effects as well as increasing remyelination and decreasing EAE score. Furthermore, curcumin can decrease the severity of MS disease by blocking IL-12 signaling pathway in T cells. Side effects of curcumin is associated with high dose consumption which causes nausea and diarrhea. Although, therapeutic effects of curcumin were demonstrated in different studies but human studies are certainly needed to confirm the recommendation of curcumin in MS patients.

**Hypericum perforatum**

*Hypericum perforatum* L. better known as St John’s Wort is a flowering plant from the family Hypericaceae. *H. perforatum* is a native plant in Europe and Asia but today has worldwide spread. From the ancient time, *H. perforatum* was popular plant because it had a wide range of therapeutic effects for different diseases such as anxiety, depression and menstrual disorders. Currently, *H. perforatum* is used for treating the antidepressant-related disorders, cancers and neurodegenerative diseases. The usage of *H. perforatum* in MS disease is related to its antidepressant effects. Hypericin is the main antidepressant component of *H. perforatum* which stimulates capillary blood flow in brain. Studies have showed that Hypericin strongly inhibits the MAO enzymes and has a strong affinity for Sigma receptors which regulate dopamine level. Recent studies have shown that hypericin acts as an antagonist for adenosine, benzodiazepine and GABA receptors. Many studies emphasis on another constituent, Hyperforin, for the therapeutic effects of this plant. It has been reported that Hyperforin has antidepressant effects as a result of inhibiting the uptake of dopamine, serotonin, noradrenaline, GABA, and L-glutamate. There are some clinical studies which have shown the effectiveness of *H. perforatum* on depression conditions. Hyperforin can be recommended to MS patients due to its antidepressant, antioxidative and anti-inflammatory effects.

**Valeriana officinalis**

*Valeriana officinalis* L. (Valerian) is native to Europe, North America and parts of Asia. Valerian is a plant in the family of Caprifoliaceae, the root and rhizome of this herb are used for different medicinal purposes. In ancient Greek, valerian had various medicinal applications, for example, for digestive problems, epilepsy and urinary tract infections. In addition, valerian was introduced as a treatment for sleeping problems and insomnia. Sleep disturbance is the most important cause of fatigue in MS patients. Clinical trials demonstrated that major component of *V. officinalis* root extract, valerenic acid, is effective in treatment of mild-to-moderate sleeping disorders. Like benzodiazepines which are GABA- analogs, valerenic acid has particular affinity for the GABA$_A$ receptor. Limited adverse effects such as stomachache and allergic reaction have been observed in patients under treatment of valerenic acids. Consumption of *V. officinalis* can be suggested to MS patients due to the ameliorating effects on sleeping problems and fatigue status.

**Vaccinium macrocarpon**

*Vaccinium macrocarpon* (Cranberry, Large Cranberry), is a North American species of cranberry in Ericaceae family. Cranberry juice is obtained from the *V. macrocarpon* fruit. Cranberry has been traditionally used for treatment of bladder and kidney disorders by Native Americans. MS patients are susceptible to the urinary tract colonizations (UTC) and urinary tract infections (UTIs), as a result of the bladder dysfunction in MS disease. Studies have shown that cranberry juice or its produced-capsules is a beneficial remedy for treatment of UTIs. It has been reported that cranberry can inhibit *Escherichia coli* adherence to the urethra. Cranberry has two substantial compounds, fructose and proanthocyanidin, that stick to the fimbriae of *E. coli* and effectively hindering the bacteria’s ability to attach to the urethra. There are a few clinical studies that examined the preventive effects of cranberry on UTIs in MS patients. However, in different studies cranberry was found to be effective against urinary tract infections, but in one clinical trial of MS patients, it not showed acceptable prevention from urinary tract infections.

**Nigella sativa**

*Nigella sativa* L. usually known as black seed is widely used as a medicinal plant belongs to the family Ranunculaceae. Black seed is native to Southern Europe, Southwest Asia and North Africa. Seeds and oil of *N. sativa* has a long historical and religious background for treatment of various illnesses such as headache, back pain and gastrointestinal problems. Several studies have shown that black seed has diverse therapeutic effects, including anticancer, analgesic, antimicrobial, anti-inflammatory, renal protective and antioxidiant properties. Thymoquinone is the active compound of *N. sativa* seeds. There are several evidences that indicated the anti-inflammatory capacity of black seed oil. In vitro studies demonstrated the inhibitory effects of *N. sativa*
oil and its active compound, thymoquinone, on the production of inflammatory mediators [such as IL-1β, IL-6, TNF-a, IFN-c and PGE2]. In addition, Black seed oil inhibited COX and 5-LO pathways of arachidonate metabolism. Thymoquinone also potentially inhibiting the non-enzymatic peroxidation in brain phospholipid liposomes. The therapeutic effects of N. sativa in animal models of MS were reported. N. sativa enhanced remyelination in CNS, reduced inflammation processes and suppressed the expression of TGF β1 in EAE models of MS disease.

**Piper methysticum**

Piper methysticum (kava kava) is a psychoactive herb in the family Piperaceae, which has been used in the Pacific Islands for hundreds of years. The root of this plant is well-known for its sedative and anesthetic properties. Kava traditionally used for producing a comforting and relaxing drink. Combination of kava and valerian seems to be more comforting and relaxing drink. Kava is known for its sedative and anesthetic properties. Some evidences have indicated that kava can decrease the inflammation and fatigue, which may be useful in MS patients. Ginseng reduced the severity of EAE by inhibiting the proliferation of T cells, inhibiting the production of the inflammatory cytokines (FN-γ, IL-1β and IL-17) and depleting of CD25+ cells. In clinical studies ginseng led to fatigue improvement and had a positive effect on quality of life. Excessive intake of ginseng can lead to several adverse effects including hypertension, insomnia, rashes and diarrhea. We can deduce that kava is an effective remedy for curing MS-related fatigue and enhancing quality of life in these patients.

**Crocus sativus**

*Crocus sativus* L. (Saffron) is a flowering plant in the family Iridaceae. Saffron stigma has been widely used as a medicinal plant for healing the different disorders. Saffron has been commonly used as an herbal drug for its sedative, stimulant and anticatarrhal properties. Several studies suggested that saffron can be effective in treatment of hypertension and memory impairments. Additionally, saffron has been demonstrated anti-inflammatory and antitussive effects. Crocetin and crocin are the two main active compounds of saffron stigma, which have a wide range of therapeutic activities. Antidepressant and anti-neuroinflammatory effects of saffron are evidently effective in MS disease.

Crocin exerts its anti-inflammatory effects via inhibiting syncytin-1 and nitric oxide (NO)-induced astrocyte and oligodendrocyte cytoxicity, also decreases neurological injuries in experimental autoimmune encephalomyelitis (EAE). Syncytin-1 is highly expresses in microglia, astrocytes and glial cell of MS lesions. Studies have shown that crocin has antidepressant effects in mild to moderate depression. Excessive consumption of saffron induces dizziness, nausea, vomiting and diarrhea. Depression is a common condition in MS disease which adversely affect health status. According to this point, antidepressant activity of saffron can be highly helpful in depressive disorders of MS patients.

**Panax ginseng**

*Panax ginseng* also known as Asian ginseng is a traditional herbal medicine in Asia for thousands of years, which belongs to the Araliaceae family. Ginseng root is traditionally used in powdered form to regenerate the body and mind, increase physical strength and prevent aging. The main active compound of *P. ginseng* is ginsenosides, that exhibits anti-inflammatory, antioxidant, and anti-apoptotic properties. In addition, *P. ginseng* is one of the most useful medicinal plants for curing different neuroinflammatory diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and Multiple sclerosis.

Some evidences have indicated that ginseng can decrease the inflammation and fatigue, which may be useful in MS patients. Ginseng reduced the severity of EAE by inhibiting the proliferation of T cells, inhibiting the production of the inflammatory cytokines (FN-γ, IL-1β and IL-17) and depleting of CD25+ cells. In clinical studies ginseng led to fatigue improvement and had a positive effect on quality of life. Excessive intake of ginseng can lead to several adverse effects including hypertension, insomnia, rashes and diarrhea. We can deduce that ginseng is an effective remedy for curing MS-related fatigue and enhancing quality of life in these patients.

**Boswellia papyrifera**

*Boswellia papyrifera* belongs to the Burseraceae family. Gum production through resin of *B. papyrifera*, has high economic value. The resin of *B. papyrifera* has been traditionally used in treatment of ulcers, chronic inflammation and for memory support. The main active compound of *B. papyrifera* resin is boswellic acids. Several studies have indicated the different therapeutic effects of boswellic acids such as anti-inflammatory, antitumor and antioxidant effects.

Cognitive impairment is a common clinical symptom in MS patients, with incidence rates up to 70%. Cognitive deficits in MS patients affect various aspects including attention, information processing efficiency, processing speed, long term memory and visual learning. Anti-inflammatory and neuroprotective properties of *B. papyrifera*, reversed the cognitive impairments in MS patients. In one clinical trial, patients with MS which received *B. papyrifera*, had a significant visuospatial memory improvement compared to the control group. Administration of *B. papyrifera* enhances cognitive impairment in MS patients, but still there is a need for large scale trials to completely clarify the therapeutic effects of *B. papyrifera* in MS patients.

**Vitis vinifera**

*Vitis vinifera* L. (common grape vine) is one of the most important fruit crops in the world from the family Vitaceae. *V. vinifera* is cultivated in the most countries of Europe, Northern Africa and Western Asia. The leaves and seeds of this plant have various medicinal properties.
Resveratrol (trans-3, 4, 5-trihydroxystilbene) is a phenolic compound that produced in the grapes in response to injuries of fungal pathogens. Resveratrol has been reported to have several pharmacological effects such as anti-inflammatory, anticancer, antioxidant and antiviral properties. Both neuroprotective and anti-inflammatory effects of resveratrol were inferred in several researches. Resveratrol exhibits neuroprotective effects by inhibiting the microglia activation and decreasing the proinflammatory factors production through the MAPKs, phosphoinositide3-kinase (PI3-K)/Akt, glycogen synthase kinase-3β (GSK-3β) and NADPH oxidase signaling pathway. Resveratrol can cross the blood–brain barrier (BBB), therefore it can be an ideal candidate for treating neuroinflammatory and neurodegenerative diseases. Excessive intake of common grape causes gastrointestinal side effects including nausea, abdominal pain, flatulence and diarrhea. Neuroprotective effects of V. vinifera were demonstrated in different neurodegenerative diseases, but more specific studies on MS disease are needed to determine it’s therapeutic role in MS.

Gastrodia elata

Gastrodia elata Blume (tianma) is a saprophytic herb from the family Orchidaceae. G. elata is a traditional Chinese plant, native to the oriental countries. Tianma is the dried rhizome of the G. elata which were used as a traditional herbal medicine for a variety of conditions such as headaches, vertigo and hypertension. In addition, tianma is commonly used for the treatment of neurodegenerative disorders and memory improvement.

Due to neuroprotective and anti-neuroinflammatory effects of G. elata, it can be considered as a promising candidate for MS therapy. G. elata reduces oxygen free radicals and protects against neuronal damage. G. elata indicated anxiolytic-like properties via the GABA-ergic nervous system. It has been reported that G. elata has protective effects against global ischemia, nitric oxide synthase activity and apoptosis. Gastrodin is the main active component of the tianma which mediates its neuroprotective effects. Vanillin and Benzyl alcohol are the other active compounds of G. elata that have anti-inflammatory effects by inhibiting the generation of reactive oxygen species (ROS) and inhibiting the activities of cyclooxygenase-1 (COX-1) and COX-2. G. elata plays an important protective role in the neurorestorative processes, therefore it can be a helpful remedy for MS patients. However, future animal models and clinical studies of MS disease are needed to clarify the possible therapeutic effects of this plant on MS patients.

Camellia sinensis

Camellia sinensis L. is well known as green tea, one of the oldest beverages in the world from the Theaceae family. Dried leaves of C. sinensis are used in green tea production. Green tea is used for several different purposes including weight loss, cardiovascular disorders, inflammation and neuroprotective effects.

Green tea exhibits anti-inflammatory and neuroprotective properties. Epigallocatechin-3-gallate (EGCG) is one of the most important active compounds of green tea which is attributed to anti-inflammatory and neuroprotective properties of this plant. EGCG is a polyphenol compound that inhibits the production of inflammatory mediators such as TNF-α, IL-1β and IL-6 and improves the neuroprotection in nervous system. In other studies, EGCG inhibited LPS-induced microglial activation and protected against inflammation-mediated dopaminergic neuronal injury. Regular and habitual consumption of green tea is safe, but, consuming high doses causes liver toxicity. Green tea has anti-inflammatory effects which can protect CNS from neurodegenerative diseases such as MS. Also, green tea regulates energy expenditure in the body which may relief MS-related fatigue.

Oenothera biennis

Oenothera biennis L. (Evening primrose) is a species in the family of Onagraceae. Evening primrose oil is produced from the seeds of O. biennis which has numerous pharmacological effects. The traditional consumptions of this plant was for the treatment of swelling in the body, then were used for other problems such as skin disorders, gastro-intestinal disorders and asthma. Two parts of the plant; flowers and seeds, are used for extracting the oils. The application of Evening primrose oil in treatment of MS is related to its anti-inflammatory and immune-modulating effects. These beneficial effects largely related to the evening primrose oil abundant supply of polyunsaturated fatty acids (PUFA) content. Gamma-linolenic acid is a precursor of prostaglandin and it is responsible for anti-inflammatory effects of evening primrose oil. In clinical trials, Evening primrose oil led to significant performance improvement in the manual dexterity test. In another clinical study gamma-linolenic acid rich oil had an obvious effect in relapsing-remitting MS, which meaningfully decreased the relapse rate and the progression of disease. However, more clinical trials are needed to prove the therapeutic effects of Evening primrose oil in MS patients.

MS14 (Penaeus latisculatus, Apium graveolens and Hypericum perforatum)

MS14 is an Iranian natural herbal-marine drug, which has obvious therapeutic effects on MS patients. MS14 consists of 90% Penaeus latisculatus, 5% Apium graveolens and 5% Hypericum perforatum. In both animal models and human clinical trials, MS14 was effective in treatment of MS. Antioxidant and anti-inflammatory effects, are the two features of MS14 that halt the progression of MS disease. MS14 showed some benefits on quality of life and improvement of patients’ mobility (lower limb). The neuroprotective
and anti-inflammatory properties of MS14 were reported by suppressing the proliferation responses of T cells and decreasing the expression levels of IL-6, IL-5, IL-10, TNF-α and IL-1β. Furthermore, MS14 inhibited the inflammatory cell infiltration into the CNS and upregulated LCN2 in all stages of EAE.164,165 Oral consumption of MS14 was reported properly safe without any adverse effects.162 MS14 is an herbal-marine drug that has beneficial effects in MS disease and other neurodegenerative disorders, but still more studies are needed to find various mechanisms and pathways that MS14 shows it’s neuroprotective effects.

**Cannabis sativa**

*Cannabis sativa* L. (Bang, Marijuana, and Hachis) is a flowering plant in the genus *Cannabis* from the Cannabaceae family. *C. sativa* is native to Western and Central Asia, but extensively cultivated in Asia and Europe.166 *C. sativa* has traditionally been used for healing the different disorders such as allergies, inflammation and sexually transmitted diseases.167 Seeds, leaves and flowers of *C. sativa* was reported to have various therapeutic and medicinal values. There are numerous studies that indicated the pharmacological usage of *C. sativa*, including analgesic effect, anticancer activity, anti-inflammatory activity, central nervous system depressant activity and immunomodulatory effect.166

*C. sativa* is the most important and the most common plant which is using for treating of MS. There are numerous studies that indicated cannabinoids consumption reduced muscle stiffness, bladder disturbance, spasms, neuropathic pain and sleep disorders in MS patients.168,169 The major compound of *C. sativa* is Δ-9-tetrahydrocannabinol (THC).170 THC binds to cannabinoid receptors (CBR) in the CNS and acts as a partial agonist to CB1 and CB2 receptors.171 THC was shown to have anti-inflammatory and neuroprotective properties.167 Some studies have shown the applications of cannabinoids for improvements of spasticity in MS, consumption of cannabinoids led to significant improvement in patient-reported spasticity.172-174 Also, the combination of THC and cannabidiol (CBD) was more effective for treatment of moderate to severe refractory spasticity in MS patients.175 Cannabinoids and their synthetic drugs indicated attractive anti-inflammatory effects in animal models of MS.176 Synthetic cannabinoids can reduce inflammation by suppressing the TNF-α production in the brain. Also, Synthetic cannabinoids can improve motor function by preventing the infiltration of immune cells into the CNS, and can decrease the pro-inflammatory cytokines secretion such as IFN-γ, IL-17, IL-6, IL-1β and TNF-α.167 Sativex is a combination of the two derived cannabinoids of the *C. sativa*: THC and CBD, which has been formulated for oromucosal mouth spray to relief neuropathic pain, spasticity, sleeping difficulties, bladder disturbance and other symptoms associated with MS.177 Orally administration of THC can decrease the intensity of several signs and symptoms of MS such as, decreasing spasticity, rigidity, tremor, as well as improving walking ability, performance of handwriting and bladder control.169 Smoking marijuana in patients with MS demonstrated to have some advantageous effects, including healing the spasticity, pain, tremor and emotional dysfunction.178 In one clinical trial, cannabinoids decreased the urinary symptoms, urinary incontinence, frequency of urination and nocturia in treated group.179 There are some adverse effects associated with *C. sativa* such as the risks of cancer, cardiovascular disease, nausea, vomiting and impaired driving.61

**Conclusion**

Medicinal plants have opened a new horizon in curing neurodegenerative disorders such as Parkinson's disease, AD and MS. Literature data review indicated that herbal medicines could be effective in the treatment of MS disease and its’ related symptoms, by reducing the demyelination, improving remyelination and suppressing the inflammation in the CNS. On the basis of the above mentioned review, it can be concluded that the anti-inflammatory effect is the main reason of medicinal plants therapeutic effects in MS disease, through which medicinal plants ameliorate the severity of disease and reduce neuropathological changes. Anti-inflammatory effects of medicinal plants usually occur through inhibiting the inflammatory cell infiltration into the CNS, decreasing the production of pro-inflammatory and inflammatory cytokines. Further studies are needed to disclose the exact mechanisms of action, through which medicinal plants exhibit their anti-inflammatory and neuroprotective effects. Given that most studies of herbal therapy effects in MS have been done on animal models, still there is a great need for approving these studies by clinical trials to recommend these mentioned plants for MS patients. In addition to neuroprotective effect, medicinal plants have other beneficial effects for MS patients, such as sedation, improving sleep quality, anti-depressant effects, relief muscle stiffness and reducing bladder disturbance.

**Ethical Issues**

Not applicable.

**Conflicts of Interest**

All authors declare no conflicts of interest.

**References**

1. Camina-Tato M, Fernandez M, Morcillo-Suarez C, Navarro A, Julia E, Edo MC, et al. Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis. *J Neuroimmunol* 2010;222(1-2):70-5. doi: 10.1016/j.jneuroim.2010.03.003

2. Hasan KM, Walimuni IS, Abid H, Datta S, Wolinsky JS, Narayana PA. Human brain atlas-based multimodal MRI analysis of volumetry,
diffusimetry, relaxometry and lesion distribution in multiple sclerosis patients and healthy adult controls: Implications for understanding the pathogenesis of multiple sclerosis and consolidation of quantitative MRI results in MS. *J Neurol Sci* 2012;313(1-2):99-109. doi: 10.1016/j.jns.2011.09.015

3. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: From biology to therapy. *Nat Rev Neurosci* 2008;9(11):839-55. doi: 10.1038/nrn2480

4. Fancy SP, Kotter MR, Harrington EP, Huang JK, Zhao C, Rowitch DH, et al. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. *Exp Neurol* 2010;225(1):18-23. doi: 10.1016/j.expneurol.2009.12.020

5. Franklin RJ, Kotter MR. The biology of CNS remyelination: The key to therapeutic advances. *J Neurol* 2008;255 Suppl 1:19-25. doi: 10.1007/s00415-008-1004-6

6. Fancy SP, Zhao C, Franklin RJ. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. *Mol Cell Neurosci* 2004;27(3):247-54. doi: 10.1016/j.mcn.2004.06.015

7. Gensert JM, Goldman JE. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. *Neuron* 1997;19(1):197-203. doi: 10.1016/S0896-6273(00)80359-1

8. Nazm Bojnordi M, Ghasemi HH, Akhari E. Remyelination after lysophosphatidyl choline-induced demyelination is stimulated by bone marrow stromal cell-derived oligoprogenitor cell transplantation. *Cells Tissues Organs* 2014;200(5):300-6. doi: 10.1159/0003437350

9. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. *Curr Opin Neurol* 2001;14(3):271-8. doi: 10.1097/00019052-200106000-00003

10. Nazm Bojnordi M, Movahedin M, Tiraithi T, Javan M, Ghasemi Hamidabadi H. Oligoprogenitor cells derived from spermatogonia stem cells improve remyelination in demyelination model. *Mol Biotechnol* 2014;56(5):387-93. doi: 10.1007/s12033-013-9722-0

11. Pourabdolhossein F, Hamidabadi HG, Bojnordi MN, Mojaverrostami S. Stem cell therapy: A promising therapeutic approach for multiple sclerosis. In: Zagon IS, McLaughlin PJ, editors. Multiple sclerosis: Perspectives in treatment and pathogenesis. Brisbane (AU): Codon Publications; 2017. p. 85-108

12. Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. *J Transl Med* 2011;9(1):29. doi: 10.1186/1479-5876-9-29

13. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. *Circ Res* 2013;113(6):810-34. doi: 10.1161/CIRCRESAHA.113.300219

14. Kasarełło K, Cudnoch-Jędrzejewska A, Członkowski A, Mirowska-Guzel D. Mechanism of action of three newly registered drugs for multiple sclerosis treatment. *Pharmacol Rep* 2017;69(4):702-8. doi: 10.1016/j.pharep.2017.02.017

15. Katsavos S, Anagnostouli M. Biomarkers in multiple sclerosis: An up-to-date overview. *Mult Scler Int* 2013;2013:340508. doi: 10.1155/2013/340508

16. Salvetti M, Landsman D, Schwarz-Lam P, Comi G, Thompson AJ, Fox RJ. Progressive MS: From pathophysiology to drug discovery. *Mult Scler* 2015;21(11):1376-84. doi: 10.1177/1352458515603802

17. de Jong HJ, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, et al. Evaluating the safety of β-interferon in MS: A series of nested case-control studies. *Neurology* 2017;88(24):2310-20. doi: 10.1212/WNL.0000000000004037

18. Kim S, Chang L, Weinstock-Guttman B, Gandhi S, Jakimovski D, Carl E, et al. Complementary and alternative medicine usage by multiple sclerosis patients: Results from a prospective clinical study. *J Altern Complement Med* 2018;24(6):596-602. doi: 10.1089/acm.2017.0268

19. Dayapoglu N, Tan M. Use of complementary and alternative medicine among people with multiple sclerosis in eastern turkey. *Neurology Asia* 2016;21(1):63-71

20. Mikaili P, Mojaverrostami S, Moloudizargari M, Aghajanshakeri S. Pharmacological and therapeutic effects of mentha longifolia L. And its main constituent, menthol. *Anc Sci Life* 2013;33(2):131-8. doi: 10.4103/0257-7941.139059

21. Agyare C, Spiegler V, Asase A, Scholz M, Hempel G, Hensel A. An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, ghana. *J Ethnopharmacol* 2018;212:137-52. doi: 10.1016/j.jep.2017.10.019

22. Dehghan-Shahreza F, Beladi-Mousavi SS, Rafieian-Kopaei M. Medicinal plants and diabetic kidney disease: an updated review on the recent findings. *Immunopathol Persa* 2016;2(1):e04.

23. Mohajeri M, Sadeghizadeh M, Najafi F, Javan M. Polymerized nano-curcumin attenuates neurological symptoms in eae model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. *Neuropsychopharm* 2015;99:156-67. doi: 10.1016/j.nephraph.2015.07.013

24. Piao Y, Liang X. Chinese medicine in diabetic peripheral neuropathy: Experimental research on nerve repair and regeneration. *Evid Based Complement Alternat Med* 2012;2012:191632. doi: 10.1155/2012/191632

25. Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, Keshavarzian A. Use of herbal preparations in the
treatment of oxidant-mediated inflammatory disorders. Complement Ther Med 2007;15(3):207-16. doi: 10.1016/j.ctim.2006.06.005

26. Olsen SA. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup Ther Int 2009;16(1):57-70. doi: 10.1002/oti.266

27. Miller RE. An investigation into the management of the spasticity experienced by some patients with multiple sclerosis using acupuncture based on traditional chinese medicine. Complement Ther Med 1996;4(1):58-62. doi: 10.1016/S0965-2299(96)80058-6

28. Song L, Zhou QH, Wang HL, Liao FJ, Hua L, Zhang HF, et al. Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis. Complement Ther Med 2017;31:71-81. doi: 10.1016/j.ctim.2017.02.004

29. Claffin SB, van der Mei IAF, Taylor BV. Complementary and alternative treatments of multiple sclerosis: A review of the evidence from 2001 to 2016. J Neurol Neurosurg Psychiatry 2018;89(1):34-41. doi: 10.1136/jnnp-2016-314490

30. Beaubrun G, Gray GE. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 2000;51(9):1130-4. doi: 10.1176/appi.ps.51.9.1130

31. Wesnes KA, Ward T, McGinty A, Petrinii O. The memory enhancing effects of a ginkgo biloba/panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 2000;152(4):353-61. doi: 10.1007/s002130000533

32. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997;278(16):1327-32. doi: 10.1001/jama.1997.03550160047037

33. Venkatesan R, Ji E, Kim SY. Phytochemicals that regulate neurodegenerative disease by targeting neurotrophins: A comprehensive review. Biomed Res Int 2015;2015:814068. doi: 10.1155/2015/814068

34. Johnson SK, Diamond BJ, Rausch S, Kaufman M, Shifflett SC, Graves L. The effect of Ginkgo biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial. Explore (NY) 2006;2(1):19-24. doi: 10.1016/j.explore.2005.10.007

35. Braquet P, Esano A, Buiseine E, Hosford D, Braquet C, Koltai M. Recent progress in ginkgolide research. Med Res Rev 1991;11(3):295-355. doi: 10.1002/med.2610110303

36. Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy Of Neurology. Neurology 2014;82(12):1083-92. doi: 10.1212/WNL.0000000000002520

37. Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial. Mult Scler 2007;13(3):376-85. doi: 10.1177/1352458506071213

38. Haniadka R, Rajeev AG, Palatty PL, Arora R, Baliga MS. Zingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: A review. J Altern Complement Med 2012;18(5):440-4. doi: 10.1089/acm.2010.0737

39. Palatty PL, Haniadka R, Valder B, Arora R, Baliga MS. Ginger in the prevention of nausea and vomiting: A review. Crit Rev Food Sci Nutr 2013;53(7):659-69. doi: 10.1080/10408398.2011.553751

40. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: A short review. Food Chem Toxicol 2002;40(8):1091-7. doi: 10.1016/S0278-6915(02)00037-6

41. Eguchi A, Murakami A, Ohigashi H. Novel bioassay system for evaluating anti-oxidative activities of food items: Use of basolateral media from differentiated Caco-2 cells. Free Radic Res 2005;39(12):1367-75. doi: 10.1080/10715760500045624

42. Haniadka R, Saldanha E, Sunita V, Palatty PL, Fayad R, Baliga MS. A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe). Food Funct 2013;4(6):845-55. doi: 10.1039/c3fo30337c

43. Jafarzadeh A, Mohammadi-Kordkhayli M, Ahangar-Parvin R, Azizi V, Khoramdel-Azad H, Shamsizadeh A, et al. Ginger extracts influence the expression of IL-27 and IL-33 in the central nervous system in experimental autoimmune encephalomyelitis and ameliorates the clinical symptoms of disease. J Neuroimmunol 2014;276(1-2):80-8. doi: 10.1016/j.jneuroim.2014.08.014

44. Ha SK, Moon E, Ju MS, Kim DH, Ryu JH, Oh MS, et al. 6-Shogaol, a ginger product, modulates neuroinflammation: A new approach to neuroprotection. Neuropharmacology 2012;63(2):211-23. doi: 10.1016/j.neuropharm.2012.03.016

45. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research. Food Chem Toxicol 2008;46(2):409-20. doi: 10.1016/j.fct.2007.09.085

46. Ho SC, Chang KS, Lin CC. Anti-neuroinflammatory capacity of fresh ginger is attributed mainly to 10-gingerol. Food Chem 2013;141(3):3183-91. doi: 10.1016/j.foodchem.2013.06.010

47. Amirghofran Z. Herbal medicines for immunosuppression. Iran J Allergy Asthma Immunol 2012;11(2):111-9.

48. Srimal R, Dhawan B. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-
inflammatory agent. *J Pharm Pharmacol* 1973;25(6):447-52. doi: 10.1111/j.2042-7158.1973.tb09131.x

49. Huang HC, Jan TR, Yeh SF. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. *Eur J Pharmacol* 1992;221(2-3):381-4. doi: 10.1016/0014-2999(92)90727-L

50. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. *Anticancer res* 2003;23(1A):363-98.

51. Naidu KA, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spicis. *Mol Cell Biochem* 2002;229(1-2):19-23.

52. Xie L, Li XK, Takahara S. Curcumin has bright prospects for the treatment of multiple sclerosis. *Int Immunopharmacol* 2011;11(3):323-30. doi: 10.1016/j.intimp.2010.08.013

53. Xie L, Li XK, Funeshima-Fuji N, Kimura H, Matsumoto Y, Isaka Y, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. *Int Immunopharmacol* 2009;9(5):575-81. doi: 10.1016/j.intimp.2009.01.025

54. Natarajan C, Bright JJ. Curcumin Inhibits Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through Janus Kinase-STAT Pathway in T Lymphocytes. *J Immunol* 2002;168(12):6506-13. doi: 10.4049/jimmunol.168.12.6506

55. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). *J Altern Complement Med* 2003;9(1):161-8. doi: 10.1089/107555303321223035

56. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): Drug interactions and clinical outcomes. *Br J Clin Pharmacol* 2002;54(4):349-56. doi: 10.1046/j.1365-2125.2002.01683.x

57. Dost T, Ozkayran H, Gokalp F, Yenisey C, Birincigluglu M. The Effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat. *Dig Dis Sci* 2009;54(6):1214-21. doi: 10.1007/s10620-008-0477-6

58. Schempp CM, Kirkin V, Simon-Haarsbaus B, Kersten A, Kiss J, Termeer CC, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. *Onco gene* 2002;21(8):1242-50. doi: 10.1038/sj.onc.1205190

59. Lu YH, Du CB, Liu JW, Hong W, Wei DZ. Neuroprotective effects of Hypericum perforatum on trauma induced by hydrogen peroxide in PC12 cells. *Am J Chin Med* 2004;32(3):397-405. doi: 10.1142/S0192415X04002053

60. Wenneke U, Horn O, Taylor DM. How effective is St. John's wort? The evidence revisited. *J Clin Psychiatry* 2004;65(5):611-7. doi: 10.4088/jcp.v65n0504

61. Bowling AC. Complementary and alternative medicine in multiple sclerosis. *Continuum (Minneap Minn)* 2010;16(5 Multiple Sclerosis):78-89. doi: 10.1210/01.CON.0000389935.84660.a5

62. DerMarderosian A, Beutler JA. The Review of Natural Products. St Louis, MO: Facts and Comparisons; 2002.

63. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypercin. *Planta Med* 1984;50(3):272-4. doi: 10.1055/s-2007-969700

64. Chavez ML, Chavez PI. Saint John's wort. *Hosp Pharm* 1997;32:1621-32.

65. Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of hypericum perforatum extracts. *Psychopharmacology (Berl)* 2002;164(4):423-8. doi: 10.1007/s00213-002-1229-5

66. Zanoli P. Role of hyperforin in the pharmacological activities of St. John's wort. *CNS Drug Rev* 2004;10(3):203-18. doi: 10.1111/j.1527-3458.2004.tb00022.x

67. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. *BMJ* 1996;313(7052):253-8. doi: 10.1136/bmj.313.7052.253

68. LaFrance WC Jr, Lauterbach EC, Coffey CE, Salloway SP, Kaufer DI, Reeve A, et al. The use of herbal alternative medicines in neuropsychiatry. A report of the ANPA committee on research. *J Neuropsychiatry Clin Neurosci* 2000;12(2):177-92. doi: 10.1176/jnp.12.2.177

69. Naziroglu M, Kutluhan S, Övey İS, Aykur M, Yurekli VA. Modulation of oxidative stress, apoptosis, and calcium entry in leukocytes of patients with multiple sclerosis by hypericum perforatum. *Nutr Neurosci* 2014;17(5):214-21. doi: 10.1179/1476830513Y.0000000083

70. Brown DJ. Herbal prescriptions for better health: Your everyday guide to prevention, treatment, and care. Rocklin, CA: Prima Publishing; 1996.

71. Hsu PP. Natural medicines comprehensive database. *J Med Libr Assoc* 2002;90(1):114.

72. Fleming WE, Pollak CP. Sleep disorders in multiple sclerosis. *Semin Neurol* 2005;25(1):64-8. doi: 10.1055/s-2005-867075

73. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, LaVasseur BI, et al. The use of Valeriana officinalis (Valerian) in impulsive aggression and aggression in patients with attention-deficit/hyperactivity disorder. *J Support Oncol* 2011;9(1):24-31. doi: 10.1016/j.suponc.2010.12.008
74. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: A case report. Vet Hum Toxicol 1995;37(4):364-5.

75. Dugoua JJ, Seely D, Perri D, Mills E, Koren G. Safety and efficacy of cranberry (vaccinium macrocarpon) during pregnancy and lactation. Can J Clin Pharmacol 2008;15(1):e80-6

76. Lynch DM. Cranberry for prevention of urinary tract infections. Am Fam Physician 2004;70(11):2175-7.

77. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56(3):245-50. doi: 10.1136/jnnp.56.3.245

78. Guay DR. Cranberry and urinary tract infections. Drugs 2009;69(7):775-807. doi: 10.2165/00003495-200969070-00002

79. Liu Y, Black MA, Caron L, Camesano TA. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of escherichia coli. Biotechnol Bioeng 2006;93(2):297-305. doi: 10.1002/bit.20675

80. Schultz A. Efficacy of cranberry juice and ascorbic acid in acidifying the urine in multiple sclerosis subjects. J Community Health Nurs 1984;1(3):159-69. doi: 10.1207/s15327655jchn0103_5

81. Gallien P, Amarengo G, Benoit N, Bonnivaud V, Donzé C, Kerdraon J, et al. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: A multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler 2014;20(9):1252-9. doi: 10.1177/1352458513517592

82. Khare CP. Encyclopedia of indian medicinal plants. New York: Springer-Verlag; 2004.

83. El-Dakhakhny M. Studies on the Egyptian Nigella sativa L. IV. Some pharmacological properties of the seeds’ active principle in comparison to its dihydro compound and its polymer. Arzneimittelforschung 1965;15(10):1227-9.

84. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. Seed. Int Immunopharmacol 2005;5(13-14):1749-70. doi: 10.1016/j.intimp.2005.06.008

85. Fahmy HM, Noor NA, Mohammed FF, Elsayed AA, Radwan NM. Nigella sativa as an anti-inflammatory and promising remyelinating agent in the cortex and hippocampus of experimental autoimmune encephalomyelitis-induced rats. J Basic Appl Zool 2014;67(5):182-95. doi: 10.1016/j.jobaz.2014.08.005

86. Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.). J Pharm Biomed Anal 1999;19(5):757-62. doi: 10.1016/S0731-7085(98)00300-8

87. Noor NA, Fahmy HM, Mohammed FF, Elsayed AA, Radwan NM. Nigella sativa ameliorates inflammation and demyelination in the experimental autoimmune encephalomyelitis-induced Wistar rats. Int J Clin Exp Pathol 2015;8(6):6269-86.

88. Mansour M, Tornhamre S. Inhibition of 5-lipoxygenase and leukotriene C4 synthase in human blood cells by thymoquinone. J Enzyme Inhib Med Chem 2004;19(5):431-6. doi: 10.1080/14756360400002072

89. Houghton PJ, Zarka R, de las Heras B, Hoult JR. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med 1995;61(1):33-6. doi: 10.1055/s-2006-957994

90. El-Dakhakhny M, Madi NJ, Lembert N, Ammon HP. Nigella sativa oil, nigellone and derived thymoquinone inhibit synthesis of 5-lipoxygenase products in polymorphonuclear leukocytes from rats. J Ethnopharmacol 2002;81(2):161-4. doi: 10.1016/S0378-8741(02)00051-X

91. Williamson EM. Synergy and other interactions in phytomedicines. Phytotherapy 2001;8(5):401-9. doi: 10.1078/0944-7113-00060

92. Wheatley D. Stress-induced insomnia treated with kava and valerian: Singly and in combination. Hum Psychopharmacol 2001;16(4):353-6. doi: 10.1002/hup.299

93. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract fromPiper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994;116(4):469-74. doi: 10.1007/BF02247480

94. Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. Kava pyrones and resin: Studies on kava extract WS 1490 in rodent brain. Psychopharmacology 1994;116(4):469-74. doi: 10.1007/BF02247480

95. Bowling AC. Complementary and alternative medicine and multiple sclerosis. Demos Medical Publishing; 2006.

96. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--A randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997;30(1):1-5. doi: 10.1055/s-2007-979474

97. Rios JL, Recio MC, Giner RM, Manez S. A review of saffron and its active constituents. Phytother Res 1999;13(5):189-93.

98. Hosseinizadeh H, Younesi HM. Petal and stigma extracts of crocus sativus L. Have antinociceptive and anti-inflammatory effects in mice. BMC Pharmacol 2002;2:7. doi: 10.1186/1472-6882-4-12

99. Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis AM. The effects of crocus sativus (saffron) and its constituents on nervous system: A review. Avicenna J Phytomed 2015;5(5):376-91.

100. Abdullaev Jafarova F, Caballero-Ortega H, Riveron-Negrete L, Pereda-Miranda R, Rivera-Luna R, Manuel Hernandez J, et al. In vitro evaluation of...
101. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004;55(4):458-68. doi: 10.1002/ana.20016

102. Baker JT, Borris RP, Carté B, Cordell GA, Soejarto DD, Cragg GM, et al. Natural product drug discovery and development: New perspectives on international collaboration. J Nat Prod 1995;58(9):1325-57. doi: 10.1021/np50123a003

103. Hwang I, Ahn G, Park E, Ha D, Song JY, Lee Y. An acidic polysaccharide of panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Immunol Lett 2011;138(2):169-78. doi: 10.1016/j.imlet.2011.04.005

104. Tadesse W, Desalegn G, Alia R. Natural gum and resin bearing species of Ethiopia and their potential applications. Invest Agrar Sist Recur For 2007;16(3):211-21. doi: 10.5424/isrfr/2007163-01010

105. Mahmoudi A, Hossein-Shariatfard A, Monsef-Esfahani HR, Yazdinejad AR, Khanavi M, Roghani A, et al. Evaluation of systemic administration of Boswellia papyrifera extracts and boswellic acids. Phytomedicine 2010;17(11):862-7. doi: 10.1016/j.phymed.2010.03.003

106. Ammon HP. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytotherapy: Pharmacology and clinical uses. Wien Med Wochenschr 2007;157(13-14):315-9. doi: 10.1007/s10354-007-0428-4

107. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: Pharmacology and clinical uses. Wien Med Wochenschr 2007;157(13-14):315-9. doi: 10.1007/s10354-007-0428-4

108. Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, et al. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 2006;107(2):249-53. doi: 10.1016/j.jep.2006.03.006

109. Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C. A. Meyer. Acta Pharmacol Sin 2008;29(9):1109-18. doi: 10.1111/j.1745-7254.2008.00869.x

110. Kim MH, Lee YC, Choi SY, Cho CW, Rho J, Lee KW. The changes of ginsenoside patterns in red ginseng processed by organic Acid impregnation pretreatment. J Ginseng Res 2011;35(4):497-503. doi: 10.5142/jgr.2011.35.4.497

111. Yuan CS, Wang CZ, Wicks SM, Qi LW. Chemical and pharmacological studies of saponins with a focus on american ginseng. J Ginseng Res 2010;34(3):160-7. doi: 10.5142/jgr.2010.34.3.160

112. Cho IH. Effects of panax ginseng in neurodegenerative diseases. J Ginseng Res 2012;36(4):342-53. doi: 10.5142/jgr.2012.36.4.342

113. Hwang I, Ahn G, Park E, Ha D, Song JY, Lee Y. An acidic polysaccharide of panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Immunol Lett 2011;138(2):169-78. doi: 10.1016/j.imlet.2011.04.005

114. Etemadifar M, Sayahi F, Abtahi SH, Shemshaki H, Dorooshi GA, Goodarzi M, et al. Ginseng in the treatment of fatigue in multiple sclerosis: A randomized, placebo-controlled, double-blind pilot study. Int J Neurosci 2013;123(7):480-6. doi: 10.3109/00207454.2013.764499
cognitive impairment in multiple sclerosis. *Iran J Neurol* 2014;13(3):149-53.
215. Chiu A, Karathanos VT, Mylona A, Salta FN, Preventi F, Andrikopoulos NK. Currants (Vitis vinifera L.) content of simple phenolics and antioxidant activity. *Food Chem* 2007;102(2):516-22. doi: 10.1016/j.foodchem.2006.06.009
216. Frémont L. Biological effects of resveratrol. *Life Sci* 2000;66(8):663-73. doi: 10.1016/S0024-3205(99)00410-5
217. Das S, Das DK. Anti-inflammatory responses of resveratrol. *Inflamm Allergy Drug Targets* 2007;6(3):168-73. doi: 10.2174/187121707781696464
218. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. *Biochem Soc Trans* 2007;35(Pt 5):1156-60. doi: 10.1042/BST0351156
219. Sato F, Martinez NE, Shahid M, Rose JW, Carlson NG, Tsunoda I. Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. *Am J Pathol* 2013;183(5):1390-6. doi: 10.1016/j.ajpath.2013.07.006
220. Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. *Front Neurol* 2012;3:84. doi: 10.3389/fneur.2012.00084
221. Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. *J Neuroophthalmol* 2010;30(4):328-39. doi: 10.1097/WNO.0b013e3181f7833
222. Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, et al. Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. *Int Immunopharmacol* 2005;5(1):185-93. doi: 10.1016/j.intimp.2004.08.008
223. Meng XL, Yang JY, Chen GL, Wang LH, Zhang LJ, Wang S, et al. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. *Chem Biol Interact* 2008;174(1):51-9. doi: 10.1016/j.cbi.2008.04.015
224. Choi DK, Koppula S, Suk K. Inhibitors of microglial neurotoxicity: Focus on natural products. *Molecules* 2011;16(2):1021-43. doi: 10.3390/molecules16021021
225. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. *Ann N Y Acad Sci* 2011;1215(1):161-9. doi: 10.1111/j.1749-6632.2010.5853.x
226. Ahn EK, Jeon HJ, Lim EJ, Jung HJ, Park EH. Anti-inflammatory and anti-angiogenic activities of Gastrodia elata blume. *J Ethnopharmacol* 2007;110(3):476-82. doi: 10.1016/j.jep.2006.10.006
227. Tsai CF, Huang CL, Lin YL, Lee YC, Yang YC, Huang NK. The neuroprotective effects of an extract of Gastrodia elata. *J Ethnopharmacol* 2011;138(1):119-25. doi: 10.1016/j.jep.2011.08.064
228. Yu SJ, Kim JR, Lee CK, Han JE, Lee JH, Kim HS, et al. Gastrodia elata blume and an active component, p-hydroxybenzyl alcohol reduce focal ischemic brain injury through antioxidant related gene expressions. *Biol Pharm Bull* 2005;28(6):1016-20 doi: 10.1248/bpb.28.1016
229. Van Kampen J, Robertson H, Hagg T, Drobitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. *Exp Neurol* 2003;184(1):521-9. doi: 10.1016/j.expneurol.2003.08.002
230. Manavala A, Ramachandran U, Sundaramurthi H, Mishra M, Sze SK, Hu JM, et al. Gastrodia elata Blume (tianma) mobilizes neuro-protective capacities. *Int J Biochem Mol Biol* 2012;3(2):219-41.
231. Kim BW, Koppula S, Kim JW, Lim HW, Hwang JW, Kim IS, et al. Modulation of LPS-stimulated neuroinflammation in BV-2 microglia by Gastrodia elata: 4-hydroxybenzyl alcohol is the bioactive candidate. *J Ethnopharmacol* 2012;139(2):549-57. doi: 10.1016/j.jep.2011.11.048
232. Jung JW, Yoon BH, Oh HR, Ahn JH, Kim SY, Park SY, et al. Anxiolytic-like effects of Gastrodia elata and its phenolic constituents in mice. *Biol Pharm Bull* 2006;29(2):261-5. doi: 10.1248/bpb.29.261
233. Hsieh CL, Chen CL, Tang NY, Chuang CM, Hsieh CT, Chiang SY, et al. Gastrodia elata BL mediates the suppression of nNOS and microglia activation to protect against neuronal damage in kainic acid-treated rats. *Am J Chin Med* 2005;33(4):599-611. doi: 10.1142/S0192415X0500320X
234. Wu HQ, Xie L, Jin XN, Ge Q, Jin H, Liu GQ. The effect of vanillin on the fully amygdala-kindled seizures in the rat. *Yao Xue Xue Bao* 1989;24(7):482-6.
235. Lee JY, Jang YW, Kang HS, Moon H, Sim SS, Kim CJ. Anti-inflammatory action of phenolic compounds from Gastrodia elata root. *Arch Pharm Res* 2006;29(10):849-58. doi: 10.1007/BF02973905
236. Gramza-Michalowska A, Regula J. Use of tea extracts (Camellia sinensis) in jelly candies as polyphenols sources in human diet. *Asia Pac J Clin Nutr* 2007;16(Suppl 1):43-6.
237. Graham HN. Green tea composition, consumption, and polyphenol chemistry. *Prev Med* 1992;21(3):334-50. doi: 10.1016/0091-7435(92)90041-F
238. Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: A literature review. *Chin Med* 2010;5:13. doi: 10.1186/1749-8546-5-13
239. Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. *J Nutr* 1998;128(12):2334-40. doi: 10.1093/jn/128.12.2334
Herbal Therapy for Multiple Sclerosis

150. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT, et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. *Neurosci Lett* 2006;395(2):103-7. doi: 10.1016/j.neulet.2005.10.056

151. Neyestani TR, Gharavi A, Kalayi A. Selective effects of tea extract and its phenolic compounds on human peripheral blood mononuclear cell cytokine secretions. *Int J Food Sci Nutr* 2009;60(Suppl 1):79-88. doi: 10.1080/09637480802158184

152. Mandel SA, Avramovich-Tiros Y, Reznichenko L, Zheng H, Weinreb O, Amit T, et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. *Neurosignals* 2005;14(1-2):46-60. doi: 10.1159/000085385

153. Li R, Huang YG, Fang D, Le WD. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. *J Neurosci* 2004;78(5):723-31. doi: 10.1002/jnr.20315

154. Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, et al. Acute liver failure induced by green tea extracts: Case report and review of the literature. *Liver Transpl* 2006;12(12):1892-5. doi: 10.1002/lt.21021

155. Mähler A, Steiniger J, Bock M, Klug L, Parreidt N, Lorenz M, et al. Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: A randomized clinical trial. *Am J Clin Nutr* 2015;101(3):487-95. doi: 10.3945/ajcn.113.075309

156. Balch SA, McKenney CB, Auld DL. Evaluation of gamma-linolenic acid composition of evening primrose (Oenothera) species native to Texas. *HortScience* 2003;38(4):595-8.

157. Horrobin DF. Nutritional and medical importance of gamma-linolenic acid. *Prog Lipid Res* 1992;31(2):163-94. doi: 10.1016/0163-7827(92)90008-7

158. Rezapour-Firouzi S, Arehfosseini SR, Mehdi F, Mehrangiz EM, Baradaran B, Sadeghikhomabad E, et al. Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. *Complement Ther Med* 2013;21(5):473-80. doi: 10.1016/j.ctim.2013.06.006

159. Horrobin DF. Multiple sclerosis: The rational basis for treatment with colchicine and evening primrose oil. *Med Hypotheses* 1979;5(3):365-78. doi: 10.1016/0306-8777(79)90018-5

160. Harbige LS, Sharief MK. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. *Br J Nutr* 2007;98(S1):S46-53. doi: 10.1079/BJN200714507833010

161. Ahmadi A, Habibi G, Farrokhnia M. MS14, an iranian herbal-marine compound for the treatment of multiple sclerosis. *Chin J Integr Med* 2010;16(3):270-1. doi: 10.1007/s11655-010-0270-1

162. Naseri M, Ahmadi A, Gharegozli K, Nabavi M, Faghizadeh S, Ashtarian N, et al. A double blind, placebo-controlled, crossover study on the effect of MS14, an herbal-marine drug, on quality of life in patients with multiple sclerosis. *J Med Plant Res* 2009;3(4):271-5.

163. Tafreshi AP, Ahmadi A, Ghaffarpur M, Mostafavi H, Rezaeizadeh H, Minae B, et al. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. *Phytother Res* 2008;22(8):1083-6. doi: 10.1002/ptr.2459

164. Ebrahimi-Kalan A, Soleimani Rad J, Kafami L, Mohamadnejad D, Habibi Roudkenar M, Khaki AA, et al. MS14 down-regulates lipocalin2 expression in spinal cord tissue in an animal model of multiple sclerosis in female C57BL/6. *Iran Biomed J* 2014;18(4):196-202.

165. Ebrahimi Kalan A, Soleimani Rad J, Kafami L, Mohamadnejad D, Khaki AA, Mohammedi Roushanfekeh A. MS14, a marine herbal medicine, an immunosuppressive drug in experimental autoimmune encephalomyelitis. *Iran Red Crescent Med J* 2014;16(7):e16956. doi: 10.5812/rcmj.16956

166. Kuddus M, Ginawi IAM, Al-Hazimi A. Cannabis sativa: An ancient wild edible plant of India. *Emir J Food Agric* 2013;25(10):736-45. doi: 10.9755/efja.v25i10.16400

167. Saito VM, Rezende RM, Teixeira AL. Cannabinoid modulation of neuroinflammatory disorders. *Curr Neuropsychopharmacol* 2012;10(2):159-66. doi: 10.2174/157015912800604515

168. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. *Lancet* 2003;362(9395):1517-26. doi: 10.1016/S0140-6736(03)14738-1

169. Pertwee RG. Cannabinoids and multiple sclerosis. *Pharmacol Ther* 2002;95(2):165-74. doi: 10.1016/S0163-7258(02)00255-3

170. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. *Pharmacotherapy* 2013;33(2):195-209. doi: 10.1002/phar.1187

171. Zajicek JP, Apostol VI. Role of cannabinoids in multiple sclerosis. *CNS Drugs* 2011;25(3):187-201. doi: 10.2165/11539000-000000000000000

172. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiple sclerosis. *Curr Med Res Opin* 2006;22(8):1083-6. doi: 10.1002/ptr.2459

173. Zajicek J, Reif M, Schnelle M. Cannabis extract in the treatment of muscle stiffness and other symptoms.
symptoms in multiple sclerosis—Results of the MUSEC study. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 2009.

174. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult Scler* 2004;10(4):434-41. doi: 10.1191/1352458504ms1082oa

175. Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. *Dtsch Arztebl Int* 2012;109(29-30):495-501. doi: 10.3238/arztebl.2012.0495

176. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. *Immunopharmacology* 1994;28(3):209-14. doi: 10.1016/0162-3109(94)90056-6

177. Kmietowicz Z. Cannabis based drug is licensed for spasticity in patients with MS. *BMJ* 2010;340:c3363. doi: 10.1136/bmj.c3363

178. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. *Clin Pharmacol Ther* 1994;55(3):324-8. doi: 10.1038/clpt.1994.33

179. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. *Mult Scler* 2004;10(4):425-33. doi: 10.1191/1352458504ms1063oa